NRXS · Neuraxis, INC
$6.06
-0.47 (-7.20%)
At close · Jul 29
Going-concern doubt
— flagged May 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Neither future cash generated from operating activities, nor management's contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered probable. As a result, substantial doubt is deemed to exist about the Company's ability to continue as a going concern.”View the 10-Q filed May 12, 2026
Market Cap
$80.87M
Shares
12.38M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Brian Carrico | CEO | $839,398 |
| Dr. Thomas Carrico | Chief Regulatory Officer, Compliance Officer and Privacy Officer | $411,097 |
| Dr. Adrian Miranda | Chief Medical Officer, Senior Vice President of Science and Technology | $323,052 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Brian Carrico | CEO | $392,179 |
| Dr. Thomas Carrico | Chief Regulatory Officer, Compliance Officer and Privacy Officer | $287,196 |
| Dr. Adrian Miranda | Chief Medical Officer, Senior Vice President of Science and Technology | $284,947 |